We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

43 hedge funds and large institutions have $91.8M invested in Protagonist Therapeutics in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

64% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 11

8% more funds holding

Funds holding: 40 → 43 (+3)

0.46% more ownership

Funds ownership: 47.7% → 48.16% (+0.46%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

10% less capital invested

Capital invested by funds: $103M → $91.8M (-$10.8M)

Holders
43
Holders Change
+3
Holders Change %
+7.5%
% of All Funds
1.07%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
18
Reduced
11
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.28M
2
SAM
Senzar Asset Management
New York
+$2.92M
3
Millennium Management
Millennium Management
New York
+$2.16M
4
EAM
Eventide Asset Management
Massachusetts
+$1.34M
5
BlackRock
BlackRock
New York
+$918K

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$8.15M
2
FCMI
Foresite Capital Management III
California
-$4.44M
3
CAM
Cormorant Asset Management
Massachusetts
-$1.96M
4
SIM
Spark Investment Management
New York
-$403K
5
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$65.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$95K -$16.3K -1,524 -15%
New York State Common Retirement Fund
27
New York State Common Retirement Fund
New York
$86K -$11 -1 -0%
Wells Fargo
28
Wells Fargo
California
$67K +$7.79K +729 +14%
AIG
29
American International Group
New York
$66K +$13.4K +1,254 +27%
NFA
30
Nationwide Fund Advisors
Ohio
$49K – – –
SO
31
STRS Ohio
Ohio
$27K – – –
UBS Group
32
UBS Group
Switzerland
$19K +$14.3K +1,342 +408%
Manulife (Manufacturers Life Insurance)
33
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$13K -$65.4K -6,113 -85%
Legal & General Group
34
Legal & General Group
United Kingdom
$12K – – –
BNP Paribas Financial Markets
35
BNP Paribas Financial Markets
France
$8.18K +$7.51K +702 +3,343%
AIP
36
Ameritas Investment Partners
Nebraska
$6K – – –
Bank of Montreal
37
Bank of Montreal
Ontario, Canada
$6K +$5.6K +524 New
Barclays
38
Barclays
United Kingdom
$5K -$12.5K -1,171 -72%
Creative Planning
39
Creative Planning
Kansas
$2K – – –
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$1K -$2.04K -191 -79%
Citigroup
41
Citigroup
New York
$1K -$866 -81 -56%
MAM
42
Meeder Asset Management
Ohio
$1K +$267 +25 +46%
RCM
43
RA Capital Management
Massachusetts
– -$8.15M -636,248 Closed
FCMI
44
Foresite Capital Management III
California
– -$4.44M -346,281 Closed
SIM
45
Spark Investment Management
New York
– -$403K -31,500 Closed
Bank of America
46
Bank of America
North Carolina
– -$14.3K -1,341 -100%
TRCT
47
Tower Research Capital (TRC)
New York
– -$7.01K -656 Closed
1
2

PTGX Hedge Fund Activity: Q2 2017 in Review

43 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2017, worth a combined $91.8M — down 10% from $103M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new PTGX positions and 4 closed out — a net gain of 3 holders — while 18 added to existing stakes and 11 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $4.28M. The largest seller was RA Capital Management, exiting entirely with an estimated $8.15M sold.

  • 43 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2017, up from 40 in Q1 2017.
  • Funds reported $91.8M of Protagonist Therapeutics stock for Q2 2017, down 10% quarter-over-quarter.
  • 7 funds opened new Protagonist Therapeutics positions in Q2 2017 and 4 closed out, a net change of +3 holders.
  • The largest Protagonist Therapeutics buyer in Q2 2017 was Adage Capital Partners, an estimated $4.28M added.
  • The largest Protagonist Therapeutics seller in Q2 2017 was RA Capital Management, an estimated $8.15M sold.

Based on aggregated 13F filings for Q2 2017.